An investigation on behalf of investors of Vir Biotechnology, Inc. (NASDAQ: VIR) shares over potential securities laws violations by Vir Biotechnology, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vir Biotechnology, Inc. (NASDAQ: VIR) concerning whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Francisco, CA based Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. Vir Biotechnology, Inc. reported that its annual Total Revenue rose form $2.7 million in 2017 to 10.66 million in 2018 and that its Net Loss increased from $69.85 million in 2017 to $115.88 million in 2018.
Vir Biotechnology, Inc. went public in early October 2019 at $20.00 per share. Since then shares of Vir Biotechnology, Inc. (NASDAQ: VIR) declined to $13.39 per share on October 18, 2019.